Live
- Revanth vs Modi: Congress braces up for Modi blitzkrieg
- Vijayawada: YSRCP accused of sheltering ‘anti-Dalit’ leaders
- Ayodhya is in incomparable bliss: Modi
- 'Surya Tilak' Illuminates Ram Lalla
- New Delhi: SC to hear plea against bail to TDP chief on May 7
- MyVoice: Views of our readers 18th April 2024
- IMD forecast bodes well for agri sector
- Nellore: Tough battle on the cards in Nellore Rural constituency
- Machilipatnam: People not believing Jagan’s dramas says Chandrababu Naidu
- The inner drive to help others
DCGI okays Covovax as booster dose
DCGI has approved market authorisation to Covid-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday.
New Delhi: The Drug Controller General of India (DCGI) has approved market authorisation to Covid-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said on Monday.
The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of the escalating Covid-19 pandemic situation in some countries, an official source had said.
The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in children aged 7-11 years on June 28 last year subject to certain conditions.
